lnterStim Therapy System, Verify Evaluation System
Medtronic Neuromodulation · Decision date Oct 6, 2026
What did the FDA approve?
The FDA record lists an approval decision dated 2026-10-06 for supplement P080025/S351 to Medtronic Neuromodulation's InterStim Therapy System and Verify Evaluation System, under product code QON for an implanted electrical device intended for treatment of fecal incontinence. The supplement type is Real-Time Process, with the stated reason 'Change Design/Components/Specifications/Material,' and the source statement describes 'a new stand-alone torque wrench kit configuration (Model B31020-T).'
The identifier shows this supplement sits under the original PMA P080025; it is not an approval of the whole system. The record presents the kit configuration as the changed item only. The source does not give the wrench's specifications, how it differs from prior configurations, or independent evidence of safety or clinical effectiveness for that change.
FDA approval order statement
a new stand-alone torque wrench kit configuration (Model B31020-T)
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 6, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P080025/S351
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Neuromodulation
- Product code
- QON
- Decision code
- APPR
- Decision date
- Oct 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implanted electrical device intended for treatment of fecal incontinence.
- Applicant
- Medtronic Neuromodulation
- Product code
- QON
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P080025. Subsequent supplements may change the device or its indications.
FDA decision timeline
P080025 · Original PMA
MEDTRONIC INTERSTIM SACRAL NERVE STIMULATION THERAPY SYSTEM
P080025/S351 received
Application receipt date recorded by FDA.
P080025/S352 · Related supplement
InterStim Therapy System, Verify Evaluation System
P080025/S351 · FDA decision
Real-Time Process
P080025/S353 · Related supplement
InterStim Therapy System, Verify Evaluation System
P080025/S354 · Related supplement
InterStim Therapy System, Verify Evaluation System (SNS Bowel Neurostimulator 97800), (SNS Bowel Neurostimulators Impl
Timeline entries are records held by MedtechLedger for P080025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P080025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA approval | Mar 14, 2011 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Sep 14, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 9, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Neuromodulation
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Ms Rcw225, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P080025/S351
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


